Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 14, 2020

Preclinical data of Gilead’s remdesivir raises hope for China trials

A study by the US National Institutes of Health (NIH) has demonstrated that Gilead’s antiviral drug, remdesivir, could prevent a type of coronavirus in monkeys.


Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.

A study by the US National Institutes of Health (NIH) has demonstrated that Gilead’s antiviral drug, remdesivir, could prevent a type of coronavirus in monkeys.

Data showed that the drug prevented the Middle East respiratory syndrome coronavirus (MERS-CoV) disease when administered before infection. In infected animals, remdesivir improved their condition.

NIH noted that these results support testing of the drug against the new coronavirus that emerged in China last month, as MERS-CoV is closely related to SARS-CoV-2.

Remdesivir was originally developed to fight Ebola. Previous tests in monkeys show that the drug is an effective treatment for Ebola and Nipah viruses.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

The latest study at the National Institute of Allergy and Infectious Diseases (NIAID)’s Rocky Mountain Laboratories in Hamilton, Montana assessed the drug for the treatment of MERS coronavirus.

During the study, all untreated control animals exhibited signs of respiratory disease, while those treated 24 hours before the infection had no signs of respiratory infection or lung damage, along with lower levels of virus replication.

Compared to the control animals, those treated 12 hours after infection also showed less severe disease, lower virus levels in lungs and less lung damage.

In a statement, NIH said: “The scientists indicate that the promising study results support additional clinical trials of remdesivir for MERS-CoV and 2019-nCoV.

“At least two clinical trials of remdesivir for 2019-nCoV are underway in China, and other patients with 2019-nCoV infection have received the drug under a compassionate use protocol.”

The Biomedical Advanced Research and Development Authority (BARDA) of the US Department of Health and Human Services supported the study, along with Gilead.

NIAID published the study findings in the Proceedings of the National Academy of Sciences.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU